<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="(Shanghai) Corp., Ltd. Shanghai China [3], Shanghai Mental Health Center" exact="Shanghai Jiao Tong University" post="School of Medicine, Shanghai Key Laboratory of Psychotic Disorders"/>
 <result pre="China [3], Shanghai Mental Health Center Shanghai Jiao Tong University" exact="School of Medicine," post="Shanghai Key Laboratory of Psychotic Disorders Shanghai China Correspondence"/>
 <result pre="for clinical trials. Glybera 65 was approved by the European" exact="Food and Drug Administration" post="for the treatment of lipoprotein lipase deficiency in 2013."/>
 <result pre="the pathologies of mental disease. This work was co-supported by" exact="National Natural Science Foundation of China" post="(81571326, 81501153). Contributors: YW and JC completed the conception,"/>
 <result pre="of the full text. Funding: This work was co-supported by" exact="National Natural Science Foundation of China" post="(81571326, 81501153). Competing interests: None declared. Patient consent: Not"/>
 <result pre="a Master degree of Genomics and Ph.D. of Neuroscience from" exact="East China Normal University" post="(ECNU) in 2010 and 2016, respectively. From Sep. 2010"/>
 <result pre="2017, Yao worked at Key Laboratory of Brain Functional Genomics," exact="Ministry of Education" post="of ECNU as an assistant professor. After that, he"/>
 <result pre="Ther 2012; 20: 1831â€“ 2. 10.1038/mt.2012.194 23023051 66 collab: The" exact="Medical Letter" post="Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett"/>
</results>
